{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:32:26Z","timestamp":1792290746881,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.bone.2004.01.007","type":"journal-article","created":{"date-parts":[[2004,5,4]],"date-time":"2004-05-04T06:14:26Z","timestamp":1083651266000},"page":"881-889","source":"Crossref","is-referenced-by-count":87,"title":["Efficacy and safety of ibandronate given by intravenous injection once every 3 months"],"prefix":"10.1016","volume":"34","author":[{"given":"S","family":"Adami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Felsenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S","family":"Lorenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Coutant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.C","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.D","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2004.01.007_BIB1","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"de Groen","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2004.01.007_BIB2","first-page":"1377","article-title":"Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis","volume":"4","author":"Ettinger","year":"1998","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.bone.2004.01.007_BIB3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2036.1999.00488.x","article-title":"Alendronate gastric ulcers","volume":"13","author":"Graham","year":"1999","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bone.2004.01.007_BIB4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1053\/gast.2000.16517","article-title":"Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women","volume":"119","author":"Lanza","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bone.2004.01.007_BIB5","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1046\/j.1365-2036.2000.00887.x","article-title":"Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women","volume":"14","author":"Lanza","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bone.2004.01.007_BIB6","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","author":"Chesnut","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.01.007_BIB7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(83)91465-4","article-title":"Renal failure associated with intravenous diphosphonates","volume":"1","author":"Bounameaux","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2004.01.007_BIB8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0169-6009(91)90131-I","article-title":"Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia","volume":"15","author":"Dumon","year":"1991","journal-title":"Bone Miner."},{"key":"10.1016\/j.bone.2004.01.007_BIB9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jbmr.5650110506","article-title":"Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection","volume":"11","author":"Pecherstorfer","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.01.007_BIB10","first-page":"122a","article-title":"Influence of peak ibandronic acid concentrations after 6 mg iv administration with shortened infusion time (15 and 30 minutes) on renal safety in man","volume":"20","author":"Neugebauer","year":"2001","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bone.2004.01.007_BIB11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","article-title":"Adverse effects of bisphosphonates. A comparative review","volume":"14","author":"Adami","year":"1996","journal-title":"Drug Saf."},{"key":"10.1016\/j.bone.2004.01.007_BIB12","article-title":"Clinical assessment of intravenous ibandronate injection once every 3 months in postmenopausal osteoporosis","author":"Recker","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.bone.2004.01.007_BIB13","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2004.01.007_BIB14","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2004.01.007_BIB15","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2004.01.007_BIB16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2004.01.007_BIB17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2004.01.007_BIB18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003495-199957010-00012","article-title":"Ibandronate","volume":"57","author":"Adami","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.bone.2004.01.007_BIB19","first-page":"M406","article-title":"Compliance with alendronate treatment in an osteoporosis clinic","volume":"15","author":"Lombas","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.01.007_BIB20","first-page":"SU411","article-title":"Short-term compliance to daily alendronate treatment in 1877 patients with osteoporosis. The ECMO study","volume":"15","author":"Rold\u00e1n","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.01.007_BIB21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"Thi\u00e9baud","year":"1997","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2004.01.007_BIB22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jc.85.1.231","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2004.01.007_BIB23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2004.01.007_BIB24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S8756-3282(00)00301-X","article-title":"How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?","volume":"27","author":"Delmas","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.bone.2004.01.007_BIB25","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jc.87.4.1586","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2004.01.007_BIB26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2004.01.007_BIB27","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)"},{"key":"10.1016\/j.bone.2004.01.007_BIB28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2004.01.007_BIB29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00198-003-1409-0","article-title":"Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate","volume":"14","author":"Christiansen","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2004.01.007_BIB30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(03)00091-7","article-title":"Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens","volume":"32","author":"Tank\u00f3","year":"2003","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328204000237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328204000237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T15:28:41Z","timestamp":1549726121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328204000237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S8756328204000237"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2004.01.007","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}